“The most effective method” for Targeted Axillary Dissection – Watch the Magseed AXSANA results from the ESSO 42 Congress
What is the most appropriate treatment for patients with known positive lymph nodes after neoadjuvant chemotherapy (NAC)?
That’s the burning question behind the world-renowned AXSANA study. Speaking at the ESSO 42 congress, Prof Thorsten Kühn from the Universitätsfrauenklinik Ulm Die Filderklinik shared the impressive findings seen from the Magseed arm of that study.
AXSANA has already recorded over 4,800 patients records from 27 centres, across 7 countries, and just under 200 of those patients have been treated with Magseed. In this presentation, Prof. Kühn reveals why the Magseed results have been so impressive, discussing:
- The criteria under which a patient may become strong candidate for TAD.
- How trials such as RISAS, featuring radioactive seeds, led the way for further exploration of targeted axillary treatment with other non-wire markers.
- The pros and cons to weigh up for each node marking technology.
- How Magseed is the only device to hold significant data on both pre- and post-NAC placement.
- Why a detection rate of 98.8% removal rate across 187 patients in the AXSANA study data shows Magseed to be highly effective in this setting and extremely reproducible.
“In summary, TAD using Magseed currently appears to be the most effective method for marking the target lymph node. There’s a very good reproducibility shown in a multi-centre setting after a short learning curve” Prof. Thorsten Kühn